证券代码：688202 证券简称：美迪西 上海美迪西生物医药股份有限公司 二〇二五年九月 上海美迪西生物医药股份有限公司 议案一：关于部分募投项目终止并将剩余募集资金投入新项目、永久补充流动资金及继 议案二：关于取消公司监事会、修订《公司章程》并办理工商变更登记的议案 ......... 17 议案四：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划（草案）》 议案五：关于《上海美迪西生物医药股份有限公司 2025 年限制性股票激励计划实施考 议案六：关于提请股东大会授权董事会办理公司股权激励计划相关事宜的议案 ......... 71 上海美迪西生物医药股份有限公司 2025 年第二次临时股东大会会议资料 上海美迪西生物医药股份有限公司 为维护全体股东的合法利益，确保股东大会的正常秩序和议事效率，保证大 会的顺利进行，上海美迪西生物医药股份有限公司（以下简称"公司"）根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下 简称"《证券法》"） 《上海美迪西生物医药股份有限公司股东大会议事规则》以及 《上海美迪西生物医药股份有限公司章程》 （以下简称"《公 ...

格隆汇9月5日｜A股市场CRO概念股走强，其中，昭衍新药逼近涨停，凯莱英、诺思格、康龙化成、泰 格医药、阳光诺和涨超5%，博腾股份涨超4%，美迪西、九洲药业、药明康德、毕得医药、泓博医药、 星昊医药涨超3%。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | | 9.12 | 253亿 | 103.06 | | 002821 | 凯莱英 | 1 | 5.48 | 387亿 | 42.84 | | 301333 | 诺思格 | | 5.44 | 56.31 乙 | 17.01 | | 300759 | 康龙化成 | 1 | 5.19 | 555/Z | 22.36 | | 300347 | 泰格医药 | 1 | 5.13 | 565 7 | 20.84 | | 688621 | 阳光诺和 | 兼 | 5.03 | 88.01亿 | 109.05 | | 300363 | 博腾股份 | 资 | 4.93 | 142亿 | 64.55 | | 688202 | 美迪西 | 1 | ...

今年以来，随着国内创新药投资市场的好转，中国CRO行业正站在"底部磨底、结构分化、技术突围"的 三岔口——订单开始微增、价格止跌企稳。 据赛柏蓝统计，2025年上半年国内医药融资事件数和融资总金额分别是368件和547.45亿元，新药和生 物制品的持续升温，显示出中国医药行业向创新转型的决心。东方财富choice医疗研发外包数据统计则 显示，行业内公司2025年上半年净利润平均同比增长41.39%，其中涨幅靠前的有多家CRO为核心主业 的公司，进一步佐证了CRO行业曙光已现，而兼顾了"海外大单+差异化技术+现金流安全"的企业更有 望率先享受复苏红利。 公开信息披露显示，美迪西2025年上半年境外新签订单金额同比增长约40%，长期绑定武田、吉利德、 阿斯利康等一线药企；境外客户收入2.48亿元，同比增长31.08%，境外收入较去年同期提升9.55个百分 点。 【环球网财经综合报道】近日，上市公司美迪西（688202.SH）发布了2025年半年度报告，上半年实现 营业收入5.4亿元、同比增长3.64%，终结了此前连续下滑态势；归母净利润-1289.84万元、同比收窄 81.63%，其中二季度单季净利润164.85 ...

Group 1: Industry Overview - The healthcare sector has experienced a bifurcation, with innovative drugs reviving while consumer healthcare remains in a downturn [1][12] - The innovative drug sector has seen significant growth, with a total transaction volume of $60.8 billion in the first half of the year, a 129% increase year-on-year [2][4] - The number of innovative drug companies with a market capitalization exceeding 100 billion yuan has increased to nine [3] Group 2: Innovative Drug Companies Performance - Hengrui Medicine reported revenue of 15.76 billion yuan and a net profit of 4.45 billion yuan in the first half of the year, with a year-on-year growth of 15.88% and 29.67% respectively [5] - BeiGene achieved revenue of 17.52 billion yuan and a net profit of 450 million yuan, marking its first half-year profit since its listing [7] - China Biologic Products reported revenue of 17.57 billion yuan, a 10.7% increase year-on-year, with innovative product revenue reaching 7.8 billion yuan, up 27.2% [6] Group 3: Consumer Healthcare Challenges - The vaccine sector, particularly for Zhifei Biological, saw a 73.06% decline in revenue to 4.92 billion yuan, resulting in a net loss of 597 million yuan [12] - Other consumer healthcare companies like Opcon Vision and Anke Bio also reported revenue declines, indicating a broader trend of stagnation in the sector [13] - The decline in consumer healthcare is attributed to price wars and changing consumer perceptions regarding product efficacy [13] Group 4: CRO Industry Dynamics - The CRO sector has experienced a divergence, with leading companies like WuXi AppTec reporting significant growth while smaller firms struggle [9][11] - WuXi AppTec's revenue reached 20.8 billion yuan, with a net profit increase of 101.92% [9] - The demand for CRO services is driven by the need for customized technology platforms and compliance capabilities in high-value segments like ADC and GLP-1 [10][11]

（原标题：CRO概念涨2.88%，主力资金净流入这些股） 资金流入比率方面，德展健康、ST未名、百花医药等流入比率居前，主力资金净流入率分别为 26.23%、17.45%、16.34%。（数据宝） CRO概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 603259 | 药明康 德 | 8.02 | 4.09 | 104023.54 | 9.52 | | 600196 | 复星医 药 | 6.38 | 4.71 | 23334.50 | 7.80 | | 000813 | 德展健 康 | 10.00 | 5.70 | 12613.79 | 26.23 | | 688222 | 成都先 导 | 4.18 | 10.79 | 9380.30 | 8.11 | | 600721 | 百花医 药 | 10.06 | 14.63 | 8993.68 | 16.34 | | 300759 | 康龙化 成 | 3.57 ...

Group 1 - Technology stocks continue to rise, with significant gains in the non-ferrous metals sector, and increases in pharmaceuticals and consumer sectors [2] - In the technology sector, optical module stocks such as Tengjing Technology and Zhongji Xuchuang saw substantial increases, while the semiconductor industry chain, particularly storage chips, led the gains with companies like Huahong and Zhaoyi Innovation performing well [2] - The precious metals sector within non-ferrous metals led the gains, with stocks like Hunan Gold and Western Gold hitting the daily limit, while industrial and minor metals also saw increases with leading stocks like Zijin Mining and Luoyang Molybdenum rising [2] Group 2 - Analysts attribute the continued rise in spot gold prices to three main factors: increased expectations for a Federal Reserve rate cut in September, doubts about the Fed's independence, and structural support from global central bank gold purchases [2] - The pharmaceutical sector showed notable gains, with CRO, innovative drugs, and medical services experiencing increases, highlighted by leading stocks such as Baillie Tianheng, BeiGene, and WuXi AppTec [2] - Huafu Securities suggests focusing on three directions in the innovative drug and its industry chain: BioPharma and Pharma companies with revenue and commercialization capabilities, potential large business development targets based on technology and industry trends, and exploring cutting-edge technologies like gene therapy and small nucleic acids [3]

截至2025年9月1日午间收盘，医疗健康ETF泰康(159760)上涨2.35%，成交274.28万元。跟踪指数国证公 共卫生与医疗健康指数(980016)强势上涨2.54%，成分股长春高新(000661)上涨10.00%，健康元(600380) 上涨9.98%，华海药业(600521)上涨8.73%，百济神州(688235)，惠泰医疗(688617)等个股跟涨。 业内机构分析指出，2025年半年报披露，医疗健康行业整体呈现出"先抑后扬"的走势。此前受到集采政 策与需求波动的影响，部分细分领域业绩承压，但从二季度开始，行业底部迹象逐步显现。医疗器械板 块二季度单季利润同比下滑幅度已经收窄，三季度有望迎来新一轮增长拐点。与此同时，创新药与 CRO企业在中报中展现出强劲反弹，部分企业收入增速甚至超市场预期。这表明医疗健康行业不仅没 有失速，反而正在进入估值与业绩双重修复的关键阶段。 医疗健康ETF泰康(159760)，场外联接(A类：020093；C类：020094)； 政策的积极支持为行业反转提供了坚实基础。8月18日，国务院正式批复《中国（江苏）自由贸易试验 区生物医药全产业链开放创新发展方案》，提出要在审批 ...

Group 1 - CRO concept stocks have shown significant gains, with WuXi AppTec (02359) up 6.3% to HKD 114.7, WuXi Biologics (02269) up 6.02% to HKD 35.2, and others also experiencing notable increases [1] - Dongwu Securities reports that 22 CXO listed companies are expected to see revenue, net profit attributable to parent, and net profit excluding non-recurring gains and losses grow by 14.16%, 64.03%, and 24.82% year-on-year for the first half of 2025, respectively [1] - The second quarter of 2025 is projected to show further improvement in revenue and profit growth rates, with expected increases of 15.15% in revenue and 53.58% in net profit attributable to parent [1] Group 2 - Xiangcai Securities highlights the active performance of the innovative drug industry chain under the backdrop of national encouragement for innovation, despite ongoing pressures from medical insurance cost control [2] - The establishment of a multi-tiered payment system and the rigid demand for medical services are expected to stabilize and rebound the industry [2] - Companies such as WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics are recommended for attention in the ADC CDMO and peptide CDMO sectors [2]

Core Insights - The company, Ruizhi Pharmaceutical, reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, up 140.35% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 534 million yuan, compared to 465 million yuan in the same period of 2024, reflecting a growth of 14.75% [1] - The net profit for the first half of 2025 was 25.38 million yuan, a significant turnaround from a loss of 62.91 million yuan in the previous year, marking a 140.35% increase [1] - The gross profit margin improved to 29.01%, up 77.98% year-on-year, while the net profit margin reached 4.75%, an increase of 135.07% [1] - The total of selling, administrative, and financial expenses was 108 million yuan, accounting for 20.19% of revenue, a decrease of 6.51% from the previous year [1] Operational Improvements - The company has implemented management system optimizations and established a more stable and efficient organizational structure, enhancing collaboration across departments [3] - A significant restructuring of the business development (BD) team has occurred, expanding the team size from over 10 to nearly 30, with a focus on international markets, particularly in the U.S. and Europe [3][4] - The strategic focus has shifted to a "full-package service" model, enhancing the company's ability to provide comprehensive research and development solutions, thereby improving operational efficiency and competitive advantage in the CRO market [4]

广发证券股份有限公司 关于上海美迪西生物医药股份有限公司 "公司"）持续督导保荐机构， 根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》 《上市公司募集资金监管规则》和《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等相关规定，对美迪西本次变更部分向特定对象发行股 票募集资金用途的相关事项进行了核查，情况如下： 部分募投项目终止并将剩余募集资金投入新项目、 一、募集资金基本情况 永久补充流动资金及继续存放在募集资金专户的核查意见 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2023 年 2 月 广发证券股份有限公司（以下简称"广发证券"、"保荐机构"）作为上海美 迪西生物医药股份有限公司（以下简称"美迪西"、 （证监许可[2023]265 号），同意公司向特定对象发行 A 股股票的注册 册的批复》 单位：万元 申请。截至 2023 年 8 月 4 日止，公司募集资金总额人民币 100,000.00 万元，扣 除承销保荐费等各项发行费用 1,470.93 万元（不含增值税）后实际募集资金净额 为人民币 98,529.07 万元。立信会计师事务所（特殊普通 ...